Anti-VEGF-A Humanized Antibody | A2136

The research-grade biosimilar antibody is a recombinant humanized IgG1 kappa monoclonal without an Fc fragment. This antibody binds to the receptor-binding site of vascular endothelial growth factor A (VEGF-A) and inhibits binding with its receptors (VEGFR1 and VEGFR2). This prevents VEGF-mediated proliferation and migration of endothelial cells and angiogenesis. The original drug received FDA approval in 2006 for the treatment of wet age-related macular degeneration. The drug has also been approved to treat macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

A2136 | Anti-VEGF-A Humanized Antibody DataSheet

Antibody Target: VEGF-A

Target Alternative Name: rhuFab V2, Fab-12 variant Y0317, RhuFab, vascular endothelial growth factor A, VEGFA

Tag Line: The research-grade biosimilar antibody binds to and inhibits vascular endothelial growth factor A (VEGF-A) and thus inhibits angiogenesis. The original drug received FDA approval to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy

Category: Biosimilars

Host: Recombinant

Isotype: IgG1, kappa

Species Reactivities: Human

Immunogen Sequence: Human VEGF-A

Accession #: DB01270

Gene ID:

Appearance: Colorless liquid

Form: Liquid

Concentration: 1 mg/ml

Formulation: In PBS, pH 7.5

Purification: Protein A purified

Application: In vitro

Positive Control:

Application And Usages: In vitro studies

Country of Animal Origin: USA

Country of Manufacture: USA

Usage: For Research Use Only! Not to be used in humans.

Handling: The antibody solution should be gently mixed before use.

Western Blot Verified: FALSE

Immunocytochemistry Verified: FALSE

Immunofluorescence Verified: FALSE

Immunoprecipitation Verified: FALSE

FACS Verified: FALSE

ELISA Verified: FALSE

ChIP Verified: FALSE

Dot Blot Verified: FALSE

Flow Cytometry Verified: FALSE